Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (February 2026)

61 slides from Corbus Pharmaceuticals's investor presentation, Feb 25, 2026

  1. Slide 1: Connecting Innovation to Purpose

    Connecting Innovation to Purpose Corporate Presentation February 25, 2026 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, prod

  3. Slide 3: Key clinical readouts for 2026

    Key clinical readouts for 2026 $173M Cash, cash equivalents and investments as of November 3, 2025, and approximately 17.6M common shares issued and outstanding (~20.5M fully diluted shares) 12-week dose-range finding data in patients with obesity (n=240) CRB-913 Dose escalation data CRB-601 Clinica

  4. Slide 4: A diversified pipeline with differentiated clinical risk profiles

    Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Next-Generation Nectin-4 targeting ADC CRB-701 Next-generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Phase 3 in cervical cancer Corbus (US + Europe) Dose optimization in HNSCC, cervical &

  5. Slide 5: CRB-701 Next Generation Nectin-4 Targeting ADC

    CRB-701 Next Generation Nectin-4 Targeting ADC

  6. Slide 6: CRB-701: Re-imagining a Nectin-4 ADC

    CRB-701: Re-imagining a Nectin-4 ADC Extend ADC half-life  Reduce dosing frequency Convenience Lower DAR + longer half-life  Dose higher + longer than PADCEV® Efficacy Markedly reduced PADCEV®-associated toxicities Safety Focus on non-mUC tumors  Avoid competing with PADCEV® Strategy Summary

  7. Slide 7: CRB-701: Proprietary components, novel design

    CRB-701: Proprietary components  novel design MMAE = Monomethyl auristatin E. ADCC = antibody-dependent cellular cytotoxicity. CDC = complement dependent cytotoxicity Source(s): Modified image from Corbus data on file; Corbus data on file Novel Nectin-4 Antibody ADCC + CDC functionality Glutamine F

  8. Slide 8: Best responses seen in tumors with highest Nectin-4 expression

    Best responses seen in tumors with highest Nectin-4 expression-mUC, cervical & HNSCC1 Source(s): 1. Corbus data on file; 2. AACR 2023 Poster CRB-701 demonstrates better efficacy than EV in patient-derived tumor model expressing low levels of Nectin-42 Elevated Nectin-4 expression: urothelial, cervic

  9. Slide 9: 21-day PK comparison vs PADCEV

    Company 21-day PK Comparison % ADC % Free MMAE Cmax AUC0-21d Cmax AUC0-21d PADCEV® 1.24 mg/kg Q1W x 3 PADCEV® Benchmark 100% 100% 100% 100% 2.7 mg/kg Q3W Matched for MMAE dose (DAR) 183% 274% 35% 38% 3.6 mg/kg Q3W 2.9-fold PADCEV® ADC Dose® 228% 361% 59% 62% Key differentiator: Lower levels of free

  10. Slide 10: CRB-701: Best-in-class dosing regimen

    CRB-701: Best-in-class dosing regimen Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2023 CRB-701 Clinical Cycle Comparison Patient / Physician Convenience Combination Flexibility Dosing

  11. Slide 11: CRB-701: Corbus study design (U.S. + Europe)

    CRB-701: Corbus study design (U.S. + Europe) 1.8 mg/kg 2.7 mg/kg 3.6 mg/kg 4.5 mg/kg Completed Dose expansion (Data maturation for pivotal trial planning) Dose escalation Project Optimus (Dose optimization) Randomized to 2.7 or 3.6 mg/kg monotherapy in: HNSCC Cervical mUC CRB-701 + Keytruda® Ongoing

  12. Slide 12: U.S. incident patient population funnel

    Head & Neck Squamous Cell Carcinoma Cervical Cancer mUC 5-Year Survival Not pursuing as a stand-alone company U.S. Incident Patient Population Funnel 2025 Current Treatment Emerging indications of interest: HNSCC + cervical cancer Source: SEER Bladder Cancer; Census.gov; Weir et al., 2021; American

  13. Slide 13: ESMO 2025: Key characteristics & tumor types

    ESMO 2025: Key characteristics & tumor types Source(s): ESMO 01 Sep 2025 Data cut Baseline characteristic (as of 9/1/25 data cut) Median age (range) 60 (32-90) Sex (M/F) 50.3% / 49.7% ECOG PS 0, 1, 2 43.1% , 55.1% , 1.8% Weight in kg mean (range) 72 (32.1-132.8) Prior therapies median (range) 3 (1-9

  14. Slide 14: ESMO 2025: TEAEs ≥15%

    ESMO 2025: TEAEs ≥15% (n=167) Sources: ESMO 01 Sep 2025 Data cut Adverse Events of Interest N=167 (%) Peripheral neuropathy Broad Terms* 8.4% Eye Overall 56.9% Grade 3 9% Grade 4 & 5 0 Skin Pruritus 14.4% Dry skin 10.2% Rash 9.0% Rash maculo-papular 4.8% Dermatitis acneiform 3.6% Erythema 1.8% Derma

  15. Slide 15: ESMO 2025: Favorable emerging safety profile vs. Nectin-4-MMAE peers

    ESMO 2025: Favorable emerging safety profile vs. Nectin-4-MMAE peers Source(s): 1. NDA/BLA Multidisciplinary Review and Evaluation BLA 761137 PADCEV® (enfortumab vedotin) 2. Torras, O. Reig, et al. "652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients with metastatic urothelial carcinom

  16. Slide 16: Safety Summary

    Safety Summary *Standardized MedDRA Category Search; **decubitus ulcer, general rash, Bullous dermatitis Safety 28.7% (excluding alopecia) Low numbers of Grade ≥3 events (3/167**) Discontinuations due to eye toxicities have been low (4.2%) Best-in-class for peripheral neuropathy 8.4% (all grade 1 or

  17. Slide 17: HNSCC baseline characteristics vs. peers

    HNSCC baseline characteristics vs. peers Source(s): * ESMO 01 Sep 2025 Data cut; **ESMO ASIA data Dec 2024; *** Swiecicki et al, 2024 Baseline characteristic CRB-701* Petosemtamab** HNSCC PADCEV®*** Median age (range) 62 (35-76) 60 (31–77) 65 (33-81) Sex (M/F) 90% / 10% 79% / 21% 87% / 13% ECOG PS 0

  18. Slide 18: ESMO 2025: HNSCC waterfall plot

    ESMO 2025: HNSCC waterfall plot (n=41) Source: ESMO 01 Sep 2025 Data cut, ,Note: NE = Non-Evaluable. 2.7 mg/kg 3.6 mg/kg ORR 33.3% (4/12) 47.6% (10/21) DCR 75% 61.9% Response confirmation All confirmed 7 confirmed 3 unconfirmed: 1 discontinued and 2 ongoing ORR% = ( CR+PR) / Response evaluable patie

  19. Slide 19: ESMO 2025: HNSCC swimmer plots

    ESMO 2025: HNSCC swimmer plots (n=58) Source(s): ESMO 01 Sep 2025, *based on confirmed overall response PFS and DOR: too early to assess HNSCC HNSCC

  20. Slide 20: CRB-701 biomarker populations: Observed efficacy

    CRB-701 biomarker populations: Observed efficacy Nectin-4 Responses seen across wide range of IHC H-score expressions HPV Responses seen in HPV positive and negative patients PD(L)-1 Responses in PD(L)-1 positive and negative patients Source(s): Corbus data on file HNSCC

  21. Slide 21: Case Study #1: Clinical improvement in participant with resistant disease

    Case Study #1: Clinical improvement in participant with resistant disease Source(s): Corbus Data on file As of 22 Sep 2025 – Participant is ongoing with a PR and tumor reduction of -73% with negative NavDx ctDNA. Remaining disease is PET negative/cold – being considered as a clinical (not formal) CR

  22. Slide 22: Case Study #2: Response in patient pre-treated with petosemtamab

    Source: Corbus data on file Case Study #2: Response seen in patient pre-treated with petosemtamab Patient had a partial response (after previously showing stable disease while on petosemtamab) Patient was heavily pre-treated with 4 lines of prior therapy HNSCC Adjuvant 1st line (completed) Cisplatin

  23. Slide 23: CRB-701 compared to petosemtamab or PADCEV in 2L HNSCC

    CRB-701 compared to petosemtamab or PADCEV® in 2L HNSCC Source(s): *ESMO 01 Sep 2025 Data cut; ** Swiecicki et al, 2024; ***ESMO ASIA data Dec 2024. Petosemtamab*** HNSCC PADCEV®** CRB-701* Dosing regimen 1500mg Q2W 1.25mg/kg on d1/8/15 of 28-day 3.6mg/kg Q3W Target population PD(L)-1 +ve only (HPV+

  24. Slide 24: Target patient populations for CRB-701 in HNSCC

    Target patient populations for CRB-701 in HNSCC 1L Multiple MOAs being evaluated CRB-701 combo data with pembrolizumab  expected mid-2026 24,000* annual cases in USA No ADCs approved Orthogonal mechanism to EGFR Existing late line Tx ORR ~10-20% Petosemtamab ORR 36% 2L+ Source(s): LifeSci Consultin

  25. Slide 25: CRB-701 HNSCC: Next steps planned

    CRB-701 HNSCC: Next steps planned Convenience kit components Mid-2026 Start registrational studies Monotherapy update Q1 2026 Registrational pathway update following FDA engagement 2nd Half 2026 CRB-701 + pembrolizumab data HNSCC

  26. Slide 26: ESMO 2025: Cervical waterfall plot

    ESMO 2025: Waterfall plot (n=37) Source: ESMO 01 Sep 2025 Data cut Note: NE =Non-evaluable ORR %=( CR+PR)/ Response evaluable patients DCR % = (CR+PR+SD) /Response evaluable patients 2.7 mg/kg 3.6 mg/kg ORR 22.2% (4/18) 37.5% (6/16) DCR 66.6% 68.8% Response confirmation 2 confirmed 2 unconfirmed and

  27. Slide 27: ESMO 2025: Swimmer plots

    ESMO 2025: Swimmer plots (n=54) Source(s): ESMO 01 Sep 2025 Data cut, based on confirmed overall response PFS and DOR: too early to assess Cervical Cancer

  28. Slide 28: ESMO 2025: CRB-701 compared to Tivdak

    ESMO 2025: CRB-701 compared to Tivdak® Sources: ESMO 01 Sep 2025 Data cut *Tivdak® Package Insert CRB-701 Tivdak® Mechanism Nectin-4 ADC with MMAE payload (DAR 2) Tissue factor ADC with MMAE payload (DAR 4) Target population 2L 2L Median Age 54 (32-78) 51 (26-80) ECOG (0, 1, 2, missing) 51.9%, 48.1%

  29. Slide 29: Post-1L therapy represents unmet need with few effective modalities

    Post-1L therapy represents unmet need with few effective modalities Tivdak® considered “a standard of care” in 2L with current annualized sales of $314 million* Side effect profile + poor efficacy are limitations on Tivdak® commercial success FDA has granted CRB-701 Fast Track status in cervical can

  30. Slide 30: ESMO 2025: Bladder cancer waterfall plot

    ESMO 2025: Waterfall plot (n=23) Source: ESMO 01 Sep 2025 Data cut Note: NE = Non-Evaluable ORR% = ( CR+PR) / Response evaluable patients DCR% = (CR+PR+SD)/ Response evaluable patients 2.7 mg/kg 3.6 mg/kg ORR 50.0% (4/8) 55.6% (5/9) DCR 75.0% 88.9% Response confirmation 2 confirmed 2 unconfirmed and

  31. Slide 31: ESMO 2025 Swimmer plots

    ESMO 2025 Swimmer plots (n=27) Source(s): ESMO 01 Sep 2025 Data cut, based on confirmed overall response PFS and DOR: too early to assess Bladder Cancer

  32. Slide 32: ESMO 2025: CRB-701 compared to PADCEV monotherapy

    ESMO 2025: CRB-701 compared to PADCEV® monotherapy Sources: *ESMO 01 Sep 2025 Data cut **PADCEV® data ***All grade 3, no Grade 4/5: 1 x rash, 1 x decubitus ulcer, 1 x dermatitis bullous CRB-701* PADCEV®** Mechanism Nectin-4 ADC with MMAE payload (DAR 2) Nectin-4 ADC with MMAE payload (DAR ~3.8) Dosi

  33. Slide 33: Decision based on current competitive landscape rather than data

    Decision based on current competitive landscape rather than data Keytruda® + PADCEV® dominate mUC 1L and PADCEV® dominates mUC 2L Corbus not currently pursuing mUC as indication as a stand-alone company * 1L Keytruda® + PADCEV® Efficacy: (ORR 67.7%*) PADCEV**® Efficacy (ORR 44%) 2L+ Bladder Cancer S

  34. Slide 34: CRB-913 Daily oral small molecule targeting chronic obesity management

    CRB-913 Daily oral small molecule targeting chronic obesity management Data from Phase 1a SAD/MAD study

  35. Slide 35: Emerging unmet needs in the obesity landscape

    What are the emerging unmet needs in the obesity landscape? 64% GLP-1 discontinuation @ 1 year for obesity patients* Source: *Cartwright et al 2025, **AP Nov 2024

  36. Slide 36: CRB-913's opportunity to reshape the obesity treatment paradigm

    CRB-913's opportunity to reshape the obesity treatment paradigm Alternatives to GLP-1 for resistant/intolerant/partial-responders Lifelong weight maintenance using daily pill post weight loss Avoiding sarcopenia

  37. Slide 37: Mechanisms of action in obesity

    MOA Company Function Monotherapy weight loss? CB1 inverse agonism Corbus, Novo Appetite suppression, weight loss & muscle sparring Yes Activin Lilly, Regeneron Muscle sparing No Pan-agonist bitter taste receptor Ardvark Appetite suppression No INHBE siRNA Wave, Arrowhead Fat reduction + muscle build

  38. Slide 38: CB1 is a well-understood receptor in metabolism

    CB1 is a well-understood receptor in metabolism Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. >9K papers in PubMed on CB1 and metabolism

  39. Slide 39: CRB-913 is the first truly peripherally restricted inverse agonist

    CRB-913 is the first truly peripherally restricted inverse agonist Sources: *Corbus murine data **Corbus PK modeling CRB-913 1/50th Brain:plasma ratio CRB-913 vs. Rimonabant* 1/15th Brain level CRB-913 vs. Monlunabant* 30%⇧ Increase in peripheral levels in humans vs. Monlunabant** Monlunabant Rimona

  40. Slide 40: CRB-913 SAD/MAD study

    CRB-913 SAD/MAD study (Phase 1 unit in USA, total n=112) 9 mg 25 mg 75 mg 150 mg 300 mg 600 mg 150 mg participants with obesity 7-Day Multiple Ascending Dose (MAD) (n=48) Single Ascending Dose (SAD) (n=64) # Per Cohort Placebo: 2 CRB-913: 6 # Per Cohort Placebo: 3 CRB-913: 9 25 mg 75 mg 150 mg 150 m

  41. Slide 41: Emerging weight loss with CRB-913 in subjects with obesity

    150 mg/day OD for 7 days of dosing + additional 7 days observation = 14 days in-clinic Emerging weight loss with CRB-913 in subjects with obesity (150 mg MAD cohort) 2.9% average placebo-adjusted weight loss @ day 14 Participants reported reductions in food-related thoughts and cravings Note: Baseli

  42. Slide 42: Weight loss with CRB-913 starts early and deepens

    Weight loss with CRB-913 starts early and deepens Body Weight Change (%) Note: Baseline is defined as the last available measurement taken prior to the first dose of study drug. Percent change in body weight is defined as body weight at the given day minus body weight at baseline divided by body wei

  43. Slide 43: Signals of weight loss in all-comer participants at lower doses

    Signals of weight loss in all-comer participants in MAD cohorts at lower doses Average BMI of 28  lower potential for weight loss Note: Baseline is defined as the last available measurement taken prior to the first dose of study drug. Percent change in body weight is defined as body weight at Day 1

  44. Slide 44: CRB-913 vs. orforglipron MAD: deeper and faster weight loss?

    Emerging data CRB-913 vs. orfoglipron MAD: deeper and faster weight loss? Source: All comparator data points are approximated and based on extracted figures reported from Pratt et al 2023 and Corbus data. Data is derived from cross-trial comparison. 2mg 6mg 16mg 24mg 150mg CRB-913 Placebo-adjusted w

  45. Slide 45: CRB-913 vs. orforglipron MAD data: differentiated emerging safety

    CRB-913 vs. orfoglipron MAD data: differentiated emerging safety Adverse event CRB-913* Orfoglipron** GI tolerability Nausea None 12%-22% Constipation None 11%-23% Vomiting None 0%-18% Neuropsych CSSRS Negative Negative PHQ-9 Negative Negative GAD-7 Negative Negative * CRB-913 SAD/MAD data **Pratt e

  46. Slide 46: Contextualizing weight loss in 2 weeks across oral MAD datasets

    Drug Company placebo adjusted WL (%) Type CRB-913 (150 mg) -2.9% small molecule Orforglipron (2 mg) -1.4% small molecule Aleniglipron (5 mg) -1.3% small molecule Elecoglipron (50 mg) 0% small molecule Semaglutide (40 mg) -0.7% oral peptide VK2735 (30 mg) -1.8% oral peptide Contextualizing weight los

  47. Slide 47: Potential clinical usage (1 of 3)

    Potential clinical usage and supportive clinical or pre-clinical data (1 of 3) CRB-913 monotherapy therapy for incretin insensitive/intolerant / high-risk patients 1 Insensitive patients: only hope is non-incretin MOA Intolerant patients : CRB-913 has markedly mild GI tox High risk patients (sarcope

  48. Slide 48: Potential clinical usage (2 of 3)

    Potential clinical usage and supportive clinical or pre-clinical data (2 of 3) Combination with oral incretin agonists  potentially enhances efficacy OR improve tolerability 2

  49. Slide 49: Potential clinical usage (3 of 3)

    Potential clinical usage and supportive clinical or pre-clinical data (3 of 3) “Induction/maintenance” model: goal to potentially maintain weight loss post incretin analog therapy 3

  50. Slide 50: Weight loss from CRB-913 driven by further fat loss following semaglutide

    Source: Morningstar et al-Obesity Week 2024 Weight loss from CRB-913 driven by further fat loss following semaglutide in DIO mouse model SemaSema SemaCRB-913 At day 41 (end of study period) Sema  Sema Sema  CRB-913 Difference Weight loss (%) -13.6 -17.1 ↑25% Fat change from baseline -3.65% -8.65

  51. Slide 51: Addressable market opportunity for CRB-913

    What could the addressable market opportunity look like for CRB-913? Induction by incretin analogs  maintenance by CRB-913 And/Or Combo-therapy for additional weight loss Orthogonal MOA CRB-913 in line with previous CB1 oral drugs  mild GI AEs Source: *Cartwright et al 2025, **AP Nov 2024 % Patien

  52. Slide 52: Initiated: Phase 1b study (CANYON-1)

    Initiated: Phase 1b study CRB-913 phase 1b (CANYON-1) Monlunabant phase 2a Subjects with obesity 240 240 Location USA Canada Cohorts (all QD) Placebo, 20, 40 and 60 mg Placebo, 10, 20 and 50 mg Titration Yes No Exclude PHQ-9 > 4 at baseline Yes No Completion summer 2026 20 mg QD 20 mg QD Matching Pl

  53. Slide 53: What did we learn from the CRB-913 SAD/MAD data?

    What did we learn from the CRB-913 SAD/MAD data? CRB-913 elicits weight loss that starts early and deepens Weight loss is not driven by GI AEs Weight loss is associated with restriction to the periphery True peripheral restriction  favorable safety + tolerability

  54. Slide 54: CRB-601 Potential best-in-class avb8 mAb

    CRB-601 Potential “best-in-class” ⍺vβ8 mAb

  55. Slide 55: CRB-601 has the potential to enhance checkpoint inhibition

    CRB-601 has the potential to enhance checkpoint inhibition Convenience kit components Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

  56. Slide 56: Targeting integrin avb8 as a novel approach to regulating TGFb

    Targeting the integrin ⍺vβ8 represents a novel approach to regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

  57. Slide 57: mAbs targeting TGFb activation in the clinic

    CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage Phase 1 Phase 1/2 – study completed December 2024 Phase 1 Phase 2 HCC (read-out in 2025) Expanded Ph2 trials into muC & NSCLC Phase 1 Indications Solid Tumors Solid Tumors Solid Tumors HCC Solid Tumor

  58. Slide 58: Leadership, Upcoming Catalysts, Financials

    Leadership Upcoming Catalysts Financials

  59. Slide 59: Management team

    Management team Yuval Cohen, PhD Chief Executive Officer, Director Sean Moran, CPA, MBA Chief Financial Officer Dominic Smethurst Chief Medical Officer, MA MRCP Ian Hodgson, PhD Chief Operating Officer Christina Bertsch, M.A. Head of Human Resources Corbus co-founder and Chief Executive Officer since

  60. Slide 60: Board of Directors

    Board of Directors Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ: AVBP) Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previousl

  61. Slide 61: Upcoming anticipated corporate milestones

    CRB-701 CRB-913 CRB-601 Upcoming anticipated corporate milestones Complete Ph1 SAD/MAD Q4 2025 Start Ph1B study Q4 2025 Complete Phase 1B Summer 2026 Ph1 dose escalation Q1 2026 Regulatory update Q1 2026 Start HNSCC monotherapy Ph2/3 registrational study Mid-2026 Phase 1/2 monotherapy data Mid-2026

Corbus Pharmaceuticals Holdings — Investor Presentation (February 2026) on 6ix